Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 5896 AL 5910

Alzheimer disease in 2020

Holtzman DM, Mandelkow E, Selkoe DJ.

Cold Spring Harb Perspect Med. 2012 Nov 1;2(11):a011585. doi: 10.1101/cshperspect.a011585.

Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins

Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB.

Arch Med Res. 2012 Nov;43(8):699-704. doi: 10.1016/j.arcmed.2012.10.010. Epub 2012 Nov 3.

Deregulated Cdk5 activity is involved in inducing Alzheimer's disease

Shukla V, Skuntz S, Pant HC.

Arch Med Res. 2012 Nov;43(8):655-62. doi: 10.1016/j.arcmed.2012.10.015. Epub 2012 Nov 7.

A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse)

Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

Mol Neurobiol. 2013 Apr;47(2):711-25. doi: 10.1007/s12035-012-8375-5. Epub 2012 Nov 14.

Wnt signaling: role in Alzheimer disease and schizophrenia

Inestrosa NC, Montecinos-Oliva C, Fuenzalida M.

J Neuroimmune Pharmacol. 2012 Dec;7(4):788-807. doi: 10.1007/s11481-012-9417-5. Epub 2012 Nov 18.

Current therapeutic strategy in Alzheimer's disease

Singh S, Kushwah AS, Singh R, Farswan M, Kaur R.

Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1651-64.

Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation

Lindsley CW.

ACS Chem Neurosci. 2012 Nov 21;3(11):804-5. doi: 10.1021/cn300190f.

Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease

Fernández-Morales JC, Arranz-Tagarro JA, Calvo-Gallardo E, Maroto M, Padín JF, García AG.

ACS Chem Neurosci. 2012 Nov 21;3(11):873-83. doi: 10.1021/cn3001069. Epub 2012 Aug 29.

Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease

Lin LF, Liao MJ, Xue XY, Zhang W, Yan L, Cai L, Zhou XW, Zhou X, Luo HM.

Neurosci Bull. 2013 Feb;29(1):111-20. doi: 10.1007/s12264-012-1287-6. Epub 2012 Nov 21.

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model

Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.

Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22.

Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer's disease and some pro-oxidant induced oxidative stress in rats' brain-in vitro

Oboh G, Agunloye OM, Akinyemi AJ, Ademiluyi AO, Adefegha SA.

Neurochem Res. 2013 Feb;38(2):413-9. doi: 10.1007/s11064-012-0935-6. Epub 2012 Nov 27.

Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding

Wong WB, Lin VW, Boudreau D, Devine EB.

Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):345-58. doi: 10.1002/pds.3381. Epub 2012 Dec 6.

Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Swaminathan S, Huentelman MJ, Corneveaux JJ, Myers AJ, Faber KM, Foroud T, Mayeux R, Shen L, Kim S, Turk M, Hardy J, Reiman EM, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative and NIA-LOAD/NCRAD Family Study Group.

PLoS One. 2012;7(12):e50640. doi: 10.1371/journal.pone.0050640. Epub 2012 Dec 5.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias